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Abstract: Nitric oxide (NO/cyclic guanosine monophosphate (cGMP)-regulated cellular mechanisms
are involved in a variety of (patho-) physiological processes. One of the main effector molecules in
this system, proteinkinase G (PKG), serves as a molecular switch by phosphorylating different target
proteins and thereby turning them on or off. To date, only a few interaction partners of PKG have
been described although the identification of protein–protein interactions (PPI) is indispensable for
the understanding of cellular processes and diseases. Conventionally used methods to detect PPIs
exhibit several disadvantages, e.g., co-immunoprecipitations, which depend on suitable high-affinity
antibodies. Therefore, we established a cell-based protein-fragment complementation assay (PCA)
for the identification of PKG target proteins. Here, a reporter protein (click beetle luciferase) is
split into two fragments and fused to two different possible interaction partners. If interaction
occurs, the reporter protein is functionally complemented and the catalyzed reaction can then be
quantitatively measured. By using this technique, we confirmed the regulator of G-Protein signaling
2 (RGS2) as an interaction partner of PKGIα (a PKG-isoform) following stimulation with 8-Br-cGMP
and 8-pCPT-cGMP. Hence, our results support the conclusion that the established approach could
serve as a novel tool for the rapid, easy and cost-efficient detection of novel PKG target proteins.
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1. Introduction
Protein–protein interactions (PPI) regulate a huge variety of cellular processes, e.g., DNA
replication, diverse transport mechanisms and signal transduction networks. The entirety of all
PPIs (referred to as the interactome) of an organism was estimated in 2008, and approximately 650k
interactions were calculated [1]. The identification of the structure and regulation of PPIs is an
indispensable necessity, not only for the understanding of basic principles in cellular processes but
also for the elucidation of various diseases, as these are often related to altered PPIs. Methods to
detect PPIs range from classical in vitro procedures such as co-immunoprecipitation to modern
in vivo assays like the yeast two-hybrid system (Y2H), FRET and BRET (Foerster/bioluminescence
resonance energy transfer) as well as molecular display methods (e.g., phage displays). However,
these approaches all show certain disadvantages; for instance, the application of Y2H is restricted to
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proteins, which are transportable into the nucleus. Therefore, PPIs of, e.g., membrane proteins,
cannot be detected with Y2H. The use of protein-fragment complementation assays (PCA) can
help to circumvent this problem, as it enables the discovery of PPIs in all relevant subcellular
compartments/organelles. For this purpose, two per se inactive fragments of a reporter protein
are fused with two possible interaction partners. If the target proteins interact with each other, both
reporter fragments are arranged in close proximity and are spontaneously reconstituted to form a
functional protein. The decision which reporter protein to choose should be made with respect to the
following considerations: At first, the protein should have a small molecular weight and be monomeric.
Moreover, it should not be expressed in the used cell line (or at least there has to be a possibility to
inhibit endogenous expression). If overexpressed, the protein of choice must not be toxic for cells.
And last, simple in vitro/in vivo detection methods have to be available. One of the first described
PCA strategies involved ubiquitin-based split protein sensors [2,3]. Other non-enzymatic PCA systems
are based on the use of fluorescent proteins like green fluorescent protein (GFP). Nonetheless, as the
complementation of these fluorescent reporters is irreversible, it is not possible to analyze the kinetics
of the investigated PPI [4]. In contrast, enzyme-based PCA not only allows the dissociation of the
reporter protein fragments and hence, a real-time analysis of the analyzed interactions, but also
a marked signal amplification. Accordingly, the fusion proteins do not have to be overexpressed
and the risk of self-association of both fragments is significantly lowered compared to fluorescent
fragments [5]. Used reporter enzymes include, for example, dihydrofolate reductase, β-galactosidase
and β-lactamase [6–8]. Nowadays, luciferases are among the most popular reporter proteins, although
the signal depends on adding a specific substrate. Nonetheless, the specific properties of luciferases
allow a versatile application in PCAs: first, luciferases are composed of independent subdomains so
that association and dissociation becomes reversible [9]. Next, the quick folding of the fragments as well
as the characteristic signal amplification makes them an ideal candidate to prove weak and transient
PPIs [10]. Last, luciferase-based PCA systems enable detection, characterization and localization
of regulated or induced PPIs in cells and living organisms in real-time [11,12]. Luciferases from
different organisms show different properties. Renilla-luciferases need coelenterazine as a substrate,
which is quite unstable in air, and emits blue light (λmax: 475 nm) spectral conditions, which are
rather unfavorable [13]. In contrast, firefly and click beetle luciferases use D-luciferin, a more stable
substrate, and emit a more long-wave light (yellow to red, λmax: 575–600 nm). Moreover, click beetle
luciferases emit 10 times more photons compared to firefly luciferases, so that the signal becomes
brighter [13]. Finally, the emission spectrum of click beetle luciferases is pH-independent, making it the
ideal candidate for the detection of PPIs in vivo [14].
Here, we established a click beetle luciferase complementation assay to investigate interactions
between proteinkinase G, isoform Iα (PKGIα) and possible interaction partners using the example of
regulator of G-protein signaling 2 (RGS2). PKGs, also referred to cGMP dependent kinases (cGKs), are
coded by two different genes (prkg1 and prkg2). The prkg1-mRNA is alternatively spliced, so that this
gene gives rise to two different cytosolic isoforms of cGKI (α- and β-isoform, respectively). In contrast,
prkg2 codes for PKGII/cGKII, which is located at the intracellular site of the plasma membrane by
myristoylation [15]. Considering cGKI-isoforms, these proteins mainly differ in the first 100 amino
acids of the N-terminal region and exhibit a rod-like structure which is composed of a regulatory and
catalytic subunit [16–18]. All cGKs show a specific expression pattern and are responsible for a diversity
of cellular functions including vasorelaxation (for detailed information about expression and function
of all isoforms please refer to [19]). Before acting on different substrates, cGKs, which already exist as a
homodimer in the inactive state, must be activated by the second messenger cGMP, which mediates
possibly stronger interactions of the dimer [20,21]. More important, cGMP induces a conformational
change in the protein, so that it is no longer auto inhibited [20]. Following activation, the kinase is able
to bind specific substrates with its catalytical domain and transfer the terminal phosphate from the
donor ATP to serine or threonine residues in the substrate. Other publications point to an alternative
way to activate cGKIα: oxidants can induce an intermonomeric disulfide-bond at cysteine 42 so that
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the intermolecular interaction of both monomers of the kinase is enhanced and the dimer becomes
more stable. By forming this disulfide-bond, cGKIα might be activated without the involvement of
cGMP, a suggestion that has been controversially discussed in the past few years [22–25].
In 2003, Tang et al. identified RGS2 as a binding partner and phosphorylation target of
cGKIα [26]. These negative regulators of G-protein-coupled receptors (GPCR) accelerate hydrolysis
of G-protein-bound GTP and, therefore, terminate GPCR-induced signals [27]. Performing extensive
studies, Tang et al. showed that cGKIα binds and phosphorylates RGS2 at its N-terminal
region. Afterwards, the phosphorylated RGS2 translocates to the cell membrane to interact with
Gαq/11-subunits, which leads in turn to the termination of IP3-mediated [Ca2+]i increase and, hence,
to vasodilation [26]. Actually, RGS2-knockout mice display a hypertensive phenotype and prolonged
vasoconstrictor signaling, impressively demonstrating the important role of RGS2 in blood pressure
regulation [28]. However, the studies of Tang et al. provide only in vitro evidence for the cGKIα/RGS2
interaction, as they were using either purified cGKIα or recombinant RGS2. Some years later, it was
demonstrated in vivo that the phosphorylation of RGS2 by cGKIα is indispensable for the association
of RGS2 with the plasma membrane [29]. Nonetheless, these authors did not confirm the direct
interaction of cGKIα and RGS2 in vivo. By establishing a cell-based luciferase complementation assay,
we now further substantiate these previous findings regarding a direct interaction of cGKIα and RGS2
in vivo. Moreover, this assay is a valuable tool in future studies regarding the identification of new
PKG-substrates and extends existing methods like co-immunoprecipitation or cGMP-agarose affinity
purification, which are dependent on stable interactions between the two proteins.
2. Results
2.1. Construction of Vectors
As a basis for analyzing protein–protein interactions, we took advantage of the investigations of
Villalobos et al. and Hida et al., who showed that luciferase from click beetle (emitting red light = CBR),
with respect to reassembling and complementation, can be ideally split up in a large N-terminal
fragment consisting of aa 1–416 (CBRN) and a small C-terminal fragment consisting of aa 395–542
(CBRC), whereby the sequence overlap is necessary for reconstitution of both fragments [30–32].
We therefore cloned the cDNA of cGKIα and subsequently of RGS2 into pcDNA-vectors, which
already contained the cDNA for either CBRN or CBRC (full-length CBR vectors were kindly provided
by T. Ozawa, CBRN and CBRC split vectors were generated by Timo Littmann; primers with used
restriction sites can be found in Table S1). The attached protein can be located either at the N-terminus
or at the C-terminus of both CBRC and CBRN, and accordingly, we constructed 4 vectors for each
protein (cGKIα and RGS2, respectively). The luciferase fragments were separated from cGKIα and
RGS2, respectively, by flexible linkers consisting of Gly and Ser residues with a total length of 17 amino
acids. A schematic illustration of all vectors including used restriction sites can be found in Figure 1.
For better clarity, vectors are abbreviated hereafter as CBRC-cGKIα, cGKIα-CBRC, CBRN-cGKIα and
cGKIα-CBRN, likewise for RGS2-vectors, foregoing linker, resistance to antibiotics etc. Finally, vectors
were sequenced to verify correct sequences.
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Figure 1. Schematic illustration of cloned vectors. Used restriction enzymes and restriction sites
are indicated with dashed lines. (A) cGKIα vectors (B) RGS2 vectors; linker consists of 17 Gly and
Ser residues.
2.2. Expression in a Eukaryotic System
Next, we checked, if the expected fusion proteins can be expressed in a eukaryotic system.
Thus, we transfected COS-7-cells either with 22.5 µg of one single vector or with different
combinations of cGKIα- and RGS2-vectors with 11.25 µg of each vector (vector ratio 1:1) by means
of calcium-phosphate transfection. As control, we used non-transfected cells. After cell lysis, we
performed Western blots to verify expression of both cGKIα- and RGS2-CBR-fusion proteins, whereas
detection was performed with selective antibodies against cGKIα or RGS2. As shown in Figure 2,
all cGKIα- (Figure 2A) or RGS2-fusion proteins (Figure 2B) were expressed following transfection of
COS-7-cells. As expected, if proteins were fused to the CBRC-fragment, they appeared at a smaller
molecular weight compared to CBRN-fused proteins (expected molecular weights as calculated are
assigned on the right side of each blot). Although proteins, which were fused either with N-terminal
or C-terminal to CBRC or CRBN should have appeared at a similar molecular weight; in fact, they
differed slightly relating to their gel-running behavior. Apparently, protein folding of these fusion
proteins was variable depending on where the luciferase-tag was located. Afterwards, we analyzed
all possible combinations of cGKIα- and RGS2-vectors (Figure 2C,D). Interestingly, all combinations
of fusion proteins were expressed. As cGKIα-fusion proteins with the small CBR-fragment (CBRC)
appeared to be expressed more strongly than CBRN-fused proteins (Figure 2C), we focused on
combinations only with RGS2-fusion proteins containing the larger fragment (CBRN) in the following
interaction experiments. Interestingly, some RGS2-fragments could not be detected as single bands
(e.g., RGS2-CBRC, Figure 2D). RGS2-mRNA contains four different translation initiation sites and gives
rise to a set of different isoforms; therefore, the observed bands could be due to alternative splicing
of the RGS2-fragments [33]. However, expression of cGKIα-fusion proteins was much stronger in all
tested combinations, so that a prolonged exposure time was needed to visualize RGS2-fusion proteins
also. An equimolar amount of both interaction partners is an important prerequisite for analyzing a
possible interaction of cGKIα and RGS2 via PCA. Given this, we needed to adjust the vector ratio in
the following experiments.
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Figure 2. Expression control of cGKIα- and RGS2- fusion proteins. COS-7-cells were transfected with
the appropriate vector (22.5 µg overall DNA amount in 75 cm2 cell culture flasks). After cell lysis,
50 µg of lysate were loaded on each lane and a Western blot was performed. Fusion proteins of cGKIα
and RGS2 with CBR-fragments were detected using cGKIα- or RGS2-antibodies. (A) Expression of
cGKIα-fusion proteins. Proteins were separated using an 11.5% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE). β-Actin served as loading control. All possible fusion proteins were
found to be expressed; (B) Expression of RGS2-fusion proteins. Proteins were separated using a 12.5%
SDS-PAGE. Vinculin served as loading control. All possible fusion proteins were found to be expressed;
(C,D) Co-expression of cGKIα- and RGS2-fusion proteins. Each vector pair was co-transfected using
a 1:1 vector ratio. Proteins were separated using a 11.5% SDS-PAGE. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) served as loading control. All possible fusion proteins were found to be
expressed, while expression of cGKIα-vectors was much more intense in all tested conditions, so
that exposure time for RGS2-fusion proteins needed to be adjusted; (E) Co-expression of cGKIα- and
RGS2-fusion proteins with adjusted vector ratio. The vector pair cGKIα-CBRC and CBRN-RGS2 was
co-transfected using a 1:50 vector ratio. Proteins were separated using an 11.5% SDS-PAGE. Vinculin
served as loading control. In contrast to (C,D), exposure time for cGKIα- and RGS2-fragments did not
differ indicating that proteins were expressed in an equimolar range. kDa: calculated molecular weight
of respective fusion proteins.
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2.3. Interaction Analysis of cGKIα and RGS2
Before we could analyze the interaction between cGKIα and RGS2, we needed to establish
different controls for our experiments. As negative controls, we used four different settings, where we
either transfected both vectors without transfection reagent, transfected only one vector, or there was
no DNA at all (water control). As expected, we could not reveal any signal amplification following
stimulation with 8-Br-cGMP under these conditions (shown for one vector combination in Figure S1A).
To prove if the system was actually working, we made use of the well-known rapamycin-mediated
interaction between FKBP and FRB (FK506 binding protein and FKBP-and rapamycin binding domain
of mTOR) [30] (Figure S1B). We detected a 14-fold signal amplification 24 h after rapamycin induction.
Signal amplification was even more pronounced (38-fold) 48 h after stimulation, possibly due to a
lower basal signal and more time for protein expression. Hence, FKBP/FRB-interaction was a suitable
positive control, so that positive and negative controls were carried out in all consecutive experiments,
however, non-explicitly shown in the herein presented figures.
To determine the optimal vector ratio for cGKIα:RGS2 vectors, we examined different vector ratios
ranging from 1:2 to 1:10. However, we were not able to detect any signal amplifications following
8-Br-cGMP stimulation [34]. We concluded that expression of RGS2-fusion proteins was still too
low under these conditions, so we further intensified vector ratios to 1:25, 1:50 and 1:100; moreover,
we also tried all combinations of the different vectors of Figure 1 to find out the optimal vector
combination (Figure 3A–D). We revealed a significant signal amplification in almost all tested cases
compared to basal luminescence levels 24 h post stimulation. However, vector ratios of 1:25 to 1:50
produced more pronounced increases compared to 1:100 vector ratios. Apparently, the position of the
CBRC fragment fused to cGKIα was not an issue, as luminescence signals were quite similar between
N-terminal and C-terminal fused fragments (Figure 3A,C vs. Figure 3B,D). In contrast, at least basal
values of unstimulated cells were notably smaller if the CBRN-fragment was fused in an N-terminal
position to RGS2 (Figure 3C,D). Possibly, the C-terminal tagged RGS2 (RGS2-CBRN) has a different
binding capacity towards cGKIα and is therefore non-specifically interacting. The luminescence signal
did not differ much after cGMP stimulation in all tested conditions. Altogether, the combination
cGKIα-CBRC/CBRN-RGS2 led to the highest amplifications (ratiometric analysis on the inset of C
and D, approximately 3.5-fold amplification compared to basal luminescence). In contrast to the
positive control, a longer exposure time of the stimulus (48 h) had no influence on signal amplification
(Figure S2). Presumably, the cGMP-cGKIα-RGS2 system is already in steady-state conditions after 24 h.
In preliminary experiments, the vector combination cGKIα-CBRC/CBRN-RGS2 in a vector ratio of
1:50 produced the highest signal amplification (not shown). However, with ongoing experiments it
turned out, that a 1:25 ratio led to an even higher luminescence signal, albeit the basal luminescence
signal without stimulation with cGMP was also slightly enhanced. We checked the signal ratio of
cGMP treated to untreated cells of both conditions (1:25 and 1:50 transfected cells) which did not
differ significantly (Figure 3C,D, inset). When analyzing the protein-expression levels, we found that
a transfection ratio of 1:50 led to an almost equimolar expression of cGKIα-CBRC and CBRN-RGS2
(Figure 2E). As this vector combination produced the lowest background signal and led to a 3.5-fold
signal amplification after cGMP-stimulation, we conducted all further experiments with these vectors
in a transfection ratio of 1:50 (cGKIα-CBRC:CBRN-RGS2), with a stimulus incubation time of 24 h.
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Figure 3. Influence of vector ratio for transfection and subsequent interaction analysis of cGKIα
and RGS2: COS7-cells were seeded in 6-well plates (3.3 × 105 cells/well) and co-transfected
with 4 different combinations of cGKIα/RGS2-vectors (each transfection with 15 µg DNA, vector
ratio as indicated). After transfer to 96-well plates (1.0 × 104 cells/well) and addition of 1 mM
8-Br-cGMP, cells were incubated for 24 h. In most cases, a significant signal-increase was observed
(A–D). The most promising vector combinations for enhanced luminescence upon 8-Br-cGMP
application were CBRC-cGKIα/CBRN-RGS2 (C) and cGKIα-CBRC/CBRN-RGS2 (D); ratiometric
analysis (8-Br-cGMP-treated/untreated) can be seen on the inset of (C,D), respectively. Data is
expressed as mean ± standard error of the mean (SEM). For unpaired Student’s t-test p-values < 0.05
were considered significant (*, +), <0.01 and <0.001 highly significant (**, ++ and ***, respectively),
whereas statistical differences characterized by an + were calculated by unpaired Student’s t-test with
Welch’s correction. A non-significant difference was marked as n.s. N = technical replicates. RLU:
relative luminescence unit.
2.4. Comparison of Expression Level of cGKIα with Tissue Expression and Analysis of Activity
To check whether the expression levels of cGKIα-CBRC strongly exceed tissue concentrations
of the native protein and, therefore, could account for a false-positive signal, we transfected cells
either with cGKIα-CBRC alone, with cGKIα-CBRC and CBRN-RGS2 in combination, or with a vector
containing an untagged and, therefore, native sequence of cGKIα. We performed a Western blot
and compared the protein expression of transfected cells to the protein expression of native cGKIα
in murine tissue lysate either known to strongly express cGKIα (cerebellum) or where only a weak
expression of native cGKIα can be detected (colon), Figure 4A. While transfection with cGKIα-CBRC
alone as well as with untagged cGKIα leads to a strong overexpression compared to tissue lysates,
the co-transfected cells expressed cGKIα-CBRC at a level somewhere in between the weak and the
strong tissue expression. Hence, the established assay reflects protein expression also found in
physiological conditions. Moreover, we were also interested to see if the CBRC-tag affects activity of
the kinase (Figure 4B). Therefore, we either stimulated pre-transfected cells with 1 mM 8-Br-cGMP or
left them untreated. pVASP-Ser 239 was used to reveal cGKIα-activity. VASP (vasodilator-stimulated
phosphoprotein) is a known substrate of different kinases, which is expressed among others in platelets
and smooth muscle cells. Phosphorylation can occur at two different phosphorylation sites (Ser 157;
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Ser 239) [35,36]. The 46 kDa- band of the Ser 239 phosphorylated protein shifts in a sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to a 50 kDa band upon Ser 157 phosphorylation.
We detected a strong VASP phosphorylation at Ser 239 upon cGMP-stimulation in cells transfected
with either untagged (control-) cGKIα or with cGKIα-CBRC alone (lane 3/4 and lane 9/10). When both
interaction partners where transfected (cGKIα-CBRC + CBRN-RGS2, lane 7/8), we still observed a
faint band, yet the signal was much weaker compared to single transfections. We assumed that the
decrease in phosphorylation intensity was due to the strongly reduced cGKIα-CBRC protein expression
(since only 1/50 of DNA amount of cGKIα-CBRC was used in the co-transfections compared to single
transfections). However, the CBRC-tag does not interfere with activity of the kinase, as we detected a
massive VASP phosphorylation at Ser 239 upon cGMP stimulation, at least in cells single-transfected
with cGKIα-CBRC.
Figure 4. Comparison of expression level and activity of CBRC-tagged cGKIα. COS7-cells were
seeded in 75 cm2 culture flasks and either transfected with one vector or co-transfected with the
vector pair cGKIa-CBRC/CBRN-RGS2 (22.5 µg DNA, 1:50). 48 h post transfection, cells were either
stimulated with 1 mM 8-Br-cGMP for 1 h or left untreated. After cell lysis, 50 µg of lysate were
loaded on each lane and an 11.5% SDS-PAGE followed by Western blot was performed. cGKIα (tagged
with CBRC or untagged) was detected using cGKIα-antibodies. (A) Comparison of expression level:
murine wild-type cerebellum and colon served as positive tissue control (50 µg each). In contrast to
single transfections of either cGKIα-CBRC or untagged cGKIα, the expression level of cGKIα-CBRC
when co-transfected with CBRN-RGS2 is not enhanced compared to tissue controls. β-actin served
as loading control; (B) Analysis of activity: activity of cGKIα was shown using a p-Ser239-VASP
antibody, vinculin served as loading control. Stimulation with cGMP caused a strong p-Ser239 VASP
signal when cells were transfected with cGKIα-CBRC or untagged cGKIα alone. When cells were
co-transfected with cGKIα-CBRC/CBRN-RGS2, a weak p-Ser239 VASP signal could be detected. VASP:
vasodilator-stimulated phosphoprotein.
2.5. Comparison of Different Stimuli
Besides 8-Br-cGMP, there is also another cGMP-analog (8-pCPT-cGMP) available. Thus, we
investigated whether these two analogs in varying concentrations caused differences in signal
amplification (Figure 5). Ratiometric analysis revealed a highly significant 3.6 ± 0.3-fold signal
amplification following incubation with 1 mM 8-Br-cGMP, whereas higher or lower concentrations
were not as efficient (0.5 mM: 2.2 ± 0.2-fold amplification, 2.5 mM: 2.8 ± 0.1-fold amplification;
Figure 5A). Interestingly, already a 10 times lower concentration of 8-pCPT-cGMP led to the same
increase in luminescence compared to stimulation with 1 mM 8-Br-cGMP; we could not detect a
considerable increase by using higher concentrations (100 µM: 3.5 ± 0.1-fold amplification, 200 µM:
3.8 ± 0.1-fold amplification, 500 µM: 3.9 ± 0.3-fold amplification; Figure 5B). As 1 mM 8-Br-cGMP
and 200 µM 8-pCPT-cGMP are often used concentrations in literature, we directly compared the
signal ratios via an unpaired Student’s t-test (Figure 5C). However, we did not discover a significant
difference, indicating that both cGMP-analogs can be used in this PCA in the given concentrations.
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Figure 5. Comparison of different stimuli. COS7-cells were seeded in 6-well plates (3.3× 105 cells/well)
and co-transfected with the vector pair cGKIα-CBRC/CBRN-RGS2 (15 µg DNA, 1:50). After transfer
on 96-well plates (1.0 × 104 cells/well) cells were stimulated with different concentrations of either
8-Br-cGMP (A) or 8-pCPT-cGMP (B) and incubated for 24 h. (C) compares the ratios obtained upon
incubation with 8-Br-cGMP (1 mM) and 8-pCPT-cGMP (200 µM). Data is expressed as mean ± SEM.
For one-Way-ANOVA p-values < 0.05 were considered significant (+) < 0.001 highly significant (+++).
A non-significant difference was marked as n.s. N = technical replicates. Dashed line: signal-ratio = 1.
2.6. Analysis of Specificity
To exclude the possibility of a spontaneous complementation of the luciferase fragments and,
therefore, to prove the specificity of the established PCA systems, we added further negative controls.
Next to the already mentioned controls in Figure S1A, we also examined vector combinations of
proteins, which are so far not known to interact with each other (RGS2 with FRB and cGKIα with
FRB or FKBP) (Figure 6). Co-transfection of FRB-CRBC and CBRN-RGS2 as well as cGKIα-CBRN
and FRB-CBRC did not reveal any signals above reference (which consisted of mean value of
unstimulated cells co-transfected with the cGKIα-CBRC/CBRN-RGS2 vector combination). In contrast,
when we co-transfected cells with cGKIα-CBRC and CBRN-FKBP and left them untreated, we
observed a luminescence intensity almost comparable to stimulated cells co-transfected with
cGKIα-CBRC/CBRN-RGS2 (3158 ± 137 relative luminescence units (RLU)). The signal was further
enhanced by stimulation with 8-Br-cGMP (4231 ± 293 RLU). Accordingly, we concluded that both
proteins might interact non-specifically with each other.
Figure 6. Analysis of specificity. COS7-cells were seeded in 6-well plates (3.3 × 105 cells/well) and
co-transfected with different negative controls (in all cases 15 µg of DNA in a vector ratio of 1:50).
After transfer to 96-well plates (1.0 × 104 cells/well) cells were stimulated with 8-Br-cGMP and
incubated for 24 h. As a reference, mean value of unstimulated cells which were transfected with
cGKIα-CBRC/CBRN-RGS2 was used (dashed line, RLU = 618). Data is expressed as mean ± SEM. N =
technical replicates. RLU: relative luminescence unit.
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2.7. Analysis of Selectivity
Finally, we also aimed to verify the selectivity of the established PCA system. Thus, we stimulated
cells which were co-transfected with the favored pair of vectors with different concentrations of
8-Br-cAMP instead of 8-Br-cGMP (Figure 7). Unexpectedly, we observed highly significant signal
amplifications following all stimulations comparable to signal amplifications detected after stimulation
with 8-Br-cGMP. As depicted on the inset of the figure, the signal-ratio rises highly significant with
increasing concentrations.
Figure 7. Analysis of selectivity. COS7-cells were seeded in 6-well plates (3.3 × 105 cells/well) and
co-transfected with the vector pair cGKIα-CBRC/CBRN-RGS2 (15 µg DNA, 1:50). After transfer on
96-well plates (1.0 × 104 cells/well) cells were stimulated with different concentrations of 8-Br-cAMP
and incubated for 24 h. Data is expressed as mean ± SEM. For unpaired Student’s t-test p-values
< 0.01 and < 0.001 were considered highly significant (** and ***, respectively). A non-significant
difference was marked as n.s. N = technical replicates. RLU: relative luminescence unit. Dashed line:
signal-ratio = 1.
2.8. Dimerization of cGKIα upon Oxidant Stimulation
As already indicated, oxidative dimerization is recently discussed as a cGMP-independent way
to activate cGKIα. Already under non-oxidizing conditions, this enzyme forms a homodimer, which
is held together by its leucine-zipper domain in its regulatory N-terminal region [37]. Therefore, we
examined if H2O2 can induce this dimerization and subsequent activation in the newly established
assay, offering a direct possibility of identifying activated cGKIα. The monomers attach in parallel
to each other, and so we combined only vectors, in which the CBRC- and CBRN-fragment are fused
either both at the N-terminal or both at the C-terminal position of the kinase. We analyzed several
parameters that could influence the dimerization, e.g., number of transfected cells, applied DNA
amount, or concentration and duration of hydrogen peroxide stimulation. However, we could
not reveal significant signal amplifications probably due to high luminescence intensities already
under non-stimulating conditions [34]. We supposed that oxidation of Cys42 already occurs without
additional H2O2 stimulation. Accordingly, we performed the assay using dithiothreitol (DTT) in
two different concentrations as a reducing agent (Figure 8A). Following 1 mM DTT, both vector
combinations showed a decrease in signal intensity compared to non-reducing conditions. In contrast,
lowering the DTT concentration to 0.1 mM led to an increase in RLU to values even above the
signal obtained with non-reducing conditions. Again, we did not detect a significant reduction of
the luminescence intensities already under non-stimulating conditions compared to H2O2-treated
cells. We also analyzed the impact of hydrogen peroxide stimulation on dimerization and activity of
cGKIα using the Western blot (Figure 8B). To protect possible disulfide bonds, we used a modified
lysis buffer containing maleimide and Triton X-100 instead of lubrol as detergent. Nonetheless, we
could not notice a difference between untreated and DTT-pretreated cells. As expected, in both
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cases, stimulation with H2O2 led to a shift from monomeric (CBRN-cGKIα and CBRC-cGKIα) to
dimeric forms of cGKIα-fusion proteins. Interestingly, we detected dimeric forms already under
non-stimulating conditions, which could not be prevented by DTT. pVASP-Ser 239 was used to reveal
cGKIα-activity. We showed a slight band-shift of VASP following H2O2-stimulation, detected with a
specific Ser 239 phospho-antibody, indicating that oxidative activation of cGKIα occurred.
Figure 8. H2O2-induced cGKIα dimerization. COS7-cells were either seeded in 6-well plates
(3.3 × 105 cells/well, (A)) or in 75 cm2 culture flasks and co-transfected with the vector pairs
CBRC-cGKIα/CBRN-cGKIα (A,B) or cGKIα-CBRC/cGKIα-CBRN (A) ((A) 1.8 µg DNA, 1:1, B:
22.5 µg, 1:1). 2 h following transfection, dithiothreitol (DTT) (concentration as indicated) was added
to medium and cells were either transferred to 96-well plates before incubation (1.0 × 104 cells/well,
24 h, (A)) or directly incubated in cell culture flasks before cell harvest for Western Blot analysis
(48 h, (B)). Before cells were stimulated with H2O2 (10 min), medium was again changed to DTT-free
medium. (A) Luciferase assay. No change in luminescence signal could be observed in any condition.
Data is expressed as mean ± SEM. A non-significant difference was marked as n.s. N = technical
replicates. RLU: relative luminescence unit. (B) Western blot. Cells-lysis was performed using a
maleimide-containing buffer before separating proteins via 10% SDS-PAGE and subsequent Western
blotting. Fusion proteins of cGKIα with CBR-fragments were detected using cGKIα-antibodies,
activity of cGKIα was shown using a p-Ser239-VASP antibody, GAPDH served as loading control. No
difference in monomer- and dimer band intensity could be identified following reducing compared to
non-reducing conditions. Stimulation with hydrogen peroxide caused a shift from monomer to dimer
bands in both cases and a slightly increased band intensity of the 50 kDa-band from pVASP-Ser-239,
indicating an oxidative activation of cGKIα. VASP: vasodilator-stimulated phosphoprotein.
3. Discussion
The identification of substrates for cGMP-dependent kinases is a major prerequisite for
understanding (patho-)physiological actions of these enzymes in a molecular context and hence, for the
development of novel therapeutic strategies to overcome diseases like hypertension and coronary heart
diseases. Traditional methods to uncover interaction partners range from co-immunoprecipitation,
yeast-2-hybrid, cGMP-agarose affinity purification to phosphor-specific approaches like 32P-enzyme
assays and the use of special antibodies. However, these techniques mostly do not enable the
analysis of the dynamic cGK-signaling in cells and tissues. Therefore, we established a cell-based
luciferase-complementation assay using the example of the cGKIα-RGS2 interaction. It has been
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shown previously that the kinase binds directly to and phosphorylates RGS2 leading to its activation
and translocation to the plasma membrane [26,29]. Although we investigated a previously known
substrate with our assay, we are the first to our knowledge to provide in vivo evidence of the
cGKIα-RGS2-interaction. Initially, we figured out the optimal vector combination by comparison
of the different possibilities following 24 h incubation after transfection with or without 8-Br-cGMP
stimulation (Figure 3). As we only analyzed cGKIα-RGS2 interaction, we cannot be sure if the position
of the CBR tags also holds true for other interactions. Therefore, the vector combination has to be
determined all over again when investigating novel interaction partners of cGKIα. We examined the
influence of different stimuli in varying concentrations (Figure 5). For this purpose, we analyzed
luminescence amplification following stimulation with 8-Br-cGMP vs. 8-pCPT-cGMP using different
concentrations. We could not detect a significant difference in signal increase between the two most
commonly used concentrations of both analogues (1 mM 8-Br-cGMP vs. 200 µM 8-pCPT-cGMP).
In contrast to the bromine-substituted substance, 8-pCPT-cGMP has a more lipophilic structure,
enabling it to permeate the cell membrane more easily. Accordingly, a 5-fold lesser concentration led
to the same signal intensity. Another reason might be that 8-pCPT-cGMP has the advantage of a much
higher resistance to hydrolysis by phosphodiesterases compared to 8-Br-cGMP [38].
Next to different, more general negative controls such as transfection without DNA etc., we
also checked the specificity of the system via transfection of two fusion proteins, which are not
thought to interact with each other (Figure 6). Unexpectedly, we observed a strong luminescence
signal after transfection with CBR-fusion proteins of cGKIα and FK506 binding protein (FKBP),
which even slightly intensified (1.3 fold increase) after stimulation with 8-Br-cGMP. However, this
increase, although significant, was essentially weaker compared to the signal ratios obtained from
the cGKIα/RGS2-constructs (3.6 fold, compare also Figures 3 and 5). We concluded that we noticed
an unspecific binding of these two proteins. Wang et al. showed that FKBP-12, a small-size FKBP
family member which contains only the FK506-binding domain, binds to a glycine- and serine-rich
domain (GS-motif) of transforming growth factor β [39]. In our expression system, we also used
GS-motifs to link CBR fragments and target proteins to each other. Hence, the observed interaction
between cGKIα-CBRC and CBRN-FKBP may be explained by an unspecific binding of FKBP to the
linker-sequence in the cGKIα-CBRC fusion protein, bringing the CBRC- and CBRN-fragments in close
proximity and leading to complementation. The conspicuously high signal intensity already under
non-stimulating conditions supports this thesis, further evidence for which comes from the fact that
cells, which were transfected with cGKIα-CBRN and FRB-CBRC, do not generate an appreciable
luminescence signal.
Moreover, we also analyzed the specificity of the system using different concentrations of
8-Br-cAMP (Figure 7). Surprisingly, we discovered a highly significant signal increase in all tested
conditions comparable or even slightly higher than the values obtained upon 8-Br-cGMP stimulation.
Discrimination between the two second messengers cAMP and cGMP is a critical feature of PKA
and PKG. Nevertheless, it has been shown in numerous publications starting in the early 1980s that
cGKs can be cross-activated by cAMP, at least in vascular smooth muscle cells [40–43]. It has been
postulated that the selectivity of PKG and PKA is due to only one single amino acid exchange (A/T) in
the cyclic nucleotide-binding domain [44]. Moreover, the N-terminal cyclic nucleotide-binding domain
(CNBD-A) of human cGKI binds both cGMP and cAMP with a relatively high affinity, showing only a
two-fold preference for cGMP [45]. In contrast, the C-terminal low-affinity cyclic nucleotide-binding
domain (CNBD-B) is highly selective for cGMP binding with an EC50 of 215 nM compared to
52 µM for cAMP [46]. Physiological concentrations of cGMP and cAMP are in the range from
0.1–10 µM and about 1 µM, respectively [47,48]. However, the intracellular 8-Br-cAMP-concentration
generated via exogenous stimulation is not clear. Here, we used the commonly applicated 8-Br-cAMP
concentrations of 0.125 to 1 mM, which is 2- to 20-fold above the postulated EC50. Thereby, we
cannot exclude the possibility of cross-activation. Another option which has to be taken into account
is cross-talk between cAMP and cGMP via their degrading enzymes called phosphodiesterases
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(PDEs). While some PDE-families are known to be either cAMP- or cGMP-specific, some are also
dual-substrate specific, consequently hydrolyzing both second messengers like PDE-1, -2, -3, -10 and
-11. By activation or inhibition of such a PDE, cAMP and cGMP can influence the concentration of each
other. One interesting example is PDE10A, whose high affinity for cAMP inhibits cGMP hydrolysis
very potently so that only a low cAMP-concentration is needed to antagonize intracellular cGMP
degradation (IC50 = 0.39 µM) [49]. When studying PDE10A-transfected COS-7 cells, the authors
also detected endogenous PDE activity. Therefore, an increase in cGMP concentration upon PDE
stimulation by high amounts of cAMP might also be responsible for the signal amplifications seen
in our luciferase assay. Hence, due to its structural similarity, cAMP used in higher concentrations
could also serve as a stimulator for enzyme-complementation assays analyzing the interaction between
cGKIα and other proteins. For the proof of specificity, other intracellular messengers should be used
in future.
Finally, we turned towards an alternative stimulation of cGKIα distinct from cyclic nucleotides.
In recent years, the point of view that H2O2 is an unwanted, toxic by-product of aerobic modes of
life has changed to a more beneficial function. Meanwhile, this substance is thought to work as part
of so-called “redox-signaling” in mammalian cells, whereby different physiological responses such
as cell proliferation, differentiation and migration can be mediated (summarized in [50]). cGKIα (in
contrast to the β-isoform) can also serve as a redox sensor in cells, since the kinase dimerizes upon
oxidative stress by forming an intermonomeric disulfide bond at Cys-42. During in vitro kinase assays
using Glasstide as an artificial substrate, hydrogen oxide led to a reduced Ka of cGKIα (from 247 to
36 µM) without influencing Vmax [22]. Using a “redox-dead” cGKIα-knock-in mouse as a model,
more information is collected concerning the in vivo consequences and, thus, physiological role of this
new activation pathway. The workgroup around Philip Eaton showed inter alia an involvement in
blood pressure regulation and in cardiac diastolic relaxation, thereby fine-tuning the Frank–Starling
response [51,52]. In our lab, we also observed a highly significant increase of cGKIα dimerization
upon stimulation with H2O2 in primary mesangial cells under non-reducing conditions: While only
30% of the kinase is present as a dimer under control conditions, H2O2 massively enhances the
dimerization up to 90% (Figure S3). Accordingly, we wanted to figure out whether we can use the
herein established assay to recognize dimerization of cGKIα upon oxidant stimulation (Figure 8A).
Although we tried different conditions like variation of time and concentration for stimulation, we
could not detect any signal amplification when we co-transfected both CBRC- and CBRN-containing
cGKIα-vectors. Instead, we observed very high luminescence signals already under non-stimulating
conditions. One possible explanation is that the native, non-oxidized enzyme can already dimerize by a
non-covalent interaction of the leucine-zipper domains [37]. In this context, it is important to notice that
we already naturally lose 50% of the signal due to the design of the system. No complementation can
occur if cGKIα-monomers which carry the same CBR-fragment (2× CBRC-cGKIα or 2× CBRN-cGKIα)
dimerize. Moreover, while cultivating cells, reactive oxygen species (ROS) can be generated within
the context of a “cell-culture shock” (resulting from stresses that cells experience when they are
explanted from their natural environment into culture [53]) due to more O2 availability and missing
antioxidants in culture medium. For instance, while most eukaryotic cells in vivo are exposed to
a low O2 concentration with oxygen partial pressures ranging from 1 to 10 mmHg, cell culture is
performed in a hyperoxide atmosphere in cell incubators (up to 150 mmHg O2), thereby multiplying
ROS generation. Besides, the culture medium can even be pro-oxidant for itself, as it contains diverse
components like metal ions, which serve as powerful catalysators for forming free radicals (the problem
of oxidative stress in cell culture is comprehensively reviewed in [54]). Hence, we tried to prevent this
oxidative stress-induced dimerization of cGKIα already under non-stimulating conditions by adding
DTT to the cell-culture medium. However, when using 1 mM DTT we observed massively reduced
luminescence signals compared to non-DTT-treated cells, which could not even be amplified by the
addition of H2O2 as a stimulus. Hua Long et al. showed that thiol compounds can directly interact with
different cell-culture media (also Dulbecco’s modified Eagle medium (DMEM)) and that their oxidation
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generates hydrogen peroxide in considerable amounts [55]. As enhanced ROS production induces
DNA damage and, subsequently, cytotoxic effects, we hypothesized that addition of 1 mM DTT might
have led to cytotoxicity and thereby decrease of luminescence. However, when using a 10-fold lower
DTT-concentration, we detected even higher luminescence signals compared to non-DTT-treated cells
(underlining a function for H2O2 in cell proliferation [56]), but with 0.1 mM DTT, we could not prevent
the basal stimulation at all. It should be mentioned that the luciferase-detection reagent used also
contains DTT in an amount not further defined by the manufacturer. Accordingly, effects produced
by H2O2 stimulation were possibly destroyed prior to measurement of luciferase activity by resetting
the kinase in a reduced state after addition of this reagent. We also checked cGKIα dimerization
and activation in a Western blot (Figure 8B). Here, we did not find any differences between cells
pre-treated with 0.1 mM DTT compared to non-treated. Again, in contrast to the results produced
with the luciferase assay, following treatment with H2O2, the band intensity of monomers decreased
with a concomitant increase of dimer bands. Moreover, slightly enhanced VASP phosphorylation
following hydrogen peroxide incubation suggested at least a weak activation of cGKIα. Notably, we
revealed distinct dimer bands even under non-stimulating conditions, a reproducible phenomenon
in our laboratory but seen previously by others, too [22,57]. This Western blot analysis also reflected
results produced with the luciferase assay, as luminescence signals were appropriately high. Therefore,
we assume that the PCA system was already saturated by the background signal produced by the basal
interaction, so that stimulation with H2O2 could not enhance the signal further. However, in a recent
work by Kalyanaraman et al. the authors did not find any relation between oxidation-induced disulfide
formation and activation of cGKIα at all. In contrast, they stated that a loss of the redox-sensitive
cysteine only leads to a reduction in cGMP affinity [25]. Others report on redox-dependent changes
in intracellular location of the kinase: It has been shown that H2O2-treatment of myocytes leads to
a translocation of cGKIα to the plasma membrane. While WT-cGKIα redistributed to the cytosol
after some time, the so-called “redox-dead” C42S-cGKIα mutant remained predominantly at the
membrane [58]. Therefore, a lot more work has to be done to define the exact function and physiological
importance of the non-canonical activation pathway of cGKIα. For the aforementioned reasons, our
established system is not suitable for the evaluation of enhanced dimerization of cGKIα by hydrogen
peroxide. Nonetheless, the CBRN-/CBRC complementation coupled with cGKIα and RGS2 revealed
stable interaction of these proteins that is enhanced by cGMP and cAMP. Hence, the PCA can be
potentially used to gain a deeper insight into this protein interaction, e.g., with regard to temporal
and spatial changes by performing real-time assays [31]. Another aspect could be to mutate the
phosphorylation sites of RGS2 and check if the phosphorylation by cGKIα at these sites somehow
influences the interaction of both proteins. Moreover, the system could serve as a valuable tool to
identify novel protein interactions and, hence, phosphorylation targets of this kinase.
4. Materials and Methods
4.1. Materials
Materials required for cloning of vectors: Matrices for PCR: pMT3_cGKIα containing cDNA of
cGKIα [59], pCMV6_RGS2, containing cDNA of RGS2 (OriGene Technologie, Rockville, MD, USA).
Phusion® HF DNA polymerase as well as all restriction enzymes, T4 DNA ligase and used buffers:
New England BioLabs (Frankfurt am Main, Germany). dNTPs, DNA loading dyes and size markers:
Thermo Scientific (Karlsruhe, Germany). QIAquick Gel extraction kit and plasmid preparation kits:
Qiagen (Hilden, Germany). Primers were synthesized by Eurofins Genomics (Ebersberg, Germany),
a detailed table regarding used primer sequences can be found in the supplementary material.
Used bacteria for amplification: E. coli TOP10 (Invitrogen/Thermo Fisher Scientific, Rockford, IL,
USA). Full length CBR vectors were kindly provided by T. Ozawa, CBRN and CBRC split vectors were
generated by Timo Littmann [30].
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Materials required for cell culture and transfection: cell-culture medium: DMEM—high glucose
(D6546) and DMEM—Base (D5030) as well as PBS (Sigma-Aldrich Chemie, Steinheim, Germany).
Serum: FBS superior, Biochrom GmbH (Berlin, Germany). The following supplements were all
obtained from Sigma-Aldrich (Taufkirchen, Germany): antibiotics: 100 U/mL Penicillin G, 100 µg/mL
Streptomycin (P4333); MEM non-essential amino acid solution (100×), L-Glutamine solution (200 mM).
Trypsin: Trypsin-EDTA-solution (10×) (Sigma-Aldrich, Taufkirchen, Germany).
Materials required for Western blotting: Lowry protein concentration determination kit: Dc
protein assay (Bio-Rad Laboratories GmbH, Munich, Germany). PVDF-Membrane: Immobilon
(Millipore GmbH, Schwalbach, Germany. Antibodies: cGKIα: 1:500, rabbit, own production [60];
RGS2: 1:500, mouse (Santa Cruz Biotechnology, Heidelberg, Germany); p-VASP Ser239: 1:1000,
rabbit (Cell Signaling Technology, Cambridge, UK), β-Actin: 1:2500, rabbit (Abcam, Cambridge, UK);
vinculin: 1:500, mouse (R&D Systems, Wiesbaden-Nordenstadt, Germany); GAPDH: 1:1000, rabbit
(Cell Signaling Technology, Cambridge, UK); secondary antibodies: mouse IgG HRP-conjugated
(1:10000, Dianova GmbH, Hamburg, Germany); rabbit IgG HRP-conjugated (1:25,000, Dianova GmbH,
Hamburg, Germany).
Materials required for Luminescence assays: 96-well plates: CELLSTAR® 392-0024 (VWR
International. Darmstadt, Germany). Educt for luciferase reaction: Bright-GloTM luciferase
assay system (Promega, Mannheim, Germany). Rapamycin: kind gift from A. Buschauer
(Department of Pharmaceutical/Medicinal Chemistry, University of Regensburg). 8-Br-cAMP:
Sigma-Aldrich (Taufkirchen, Germany). 8-Br-cGMP and 8-pCPT-cGMP: Biolog Life Science Institute
(Bremen, Germany).
4.2. Construction of Vectors
The amplification of required DNA-sequences of cGKIα- and RGS2-cDNA was performed via
PCR using the aforementioned vectors as matrices and different combinations of primers (as indicated
in Table S1) along with simultaneous attachment of different restriction sites for subsequent cloning.
Phusion HF DNA polymerase was used to avoid amplification of false nucleotides. Amplificates were
purified using a GelExtraction Kit and cloned into pcDNA-vectors containing click beetle luciferase
fragments using standard methods. All generated vectors were sequenced by Eurofins Genomics
(Ebersberg, Germany) to verify correct sequences.
4.3. Cell Culture and Transfection
For this study, COS-7 cells were cultured in DMEM supplemented with 10% FCS and
aforementioned antibiotics and supplements at 37 ◦C in a 5% CO2 incubator to a confluency around
50%. Cells were then serum starved for 2 h and transfected with different luciferase or control vectors
using calcium phosphate transfection according to standard methods [61]. For Western blotting, cells
were transfected in 75 cm2 flasks, whereas serum was added again 16 h post transfection; 32 h later,
cells were harvested (see below). For luminescence assays, cells were transfected in 6-well-plates and
incubated for 16–18 h. Afterwards, cells were trypsinated, washed, transferred onto a 96-well-plate
(1–2 × 104 cells/well, overall volume 100 µL) and cultured until cell adhesion occurred (approximately
5 h). Cells were then exposed to different stimuli, so that the luminescence assay could be carried out.
4.4. Western Blotting
To control expression of transfected vectors, cell harvest was performed using cell scrapers and
detergent containing buffer (2% Lubrol, 20 mM Tris, 150 mM NaCl, pH 8.0; containing protease
inhibitors Leupeptin (0.5 µg/mL), Benzamindine (1 mM) and PMSF (0.3 mM)). For the analysis of
H2O2-induced dimerization of cGKIα, cells were lysed with a maleimide-containing buffer (25 mM
HEPES, 100 mM NaCl, 1 mM EDTA, 100 mM maleimide, 10% (v/v) glycerol, 1% (v/v) Triton X
100). Cells were homogenized with a 30-gauge needle and centrifuged (16500× g, 4 ◦C, 10 min).
For the comparison of expression in transfected cells and tissue, the cerebellum and colon of a male,
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10-week-old 129/Sv wild-type mouse were removed. Organs were washed with cold phosphate
buffered saline and homogenized by ultrasonification in Lubrol-lysis buffer (receipt as described
above) followed by centrifugation (15000× g, 4 ◦C, 10 min).
Protein concentration of cell- and tissue lysates was determined using an adapted version of the
method of Lowry [62]. After denaturing, 30–55 µg of protein/lane was separated in 11.5–12.5%
SDS-PAGE and subjected to Western blotting using the aforementioned dilutions of different
antibodies. The horse radish peroxidase (coupled to secondary antibodies) activity was visualized
using Clarity™ Western ECL Blotting substrate (Bio-Rad Laboratories GmbH, Munich, Germany) with
a chemiluminescence detector and its appropriate software (ChemiDoc MP System with ImageLab,
Bio-Rad Laboratories GmbH, Munich, Germany).
4.5. Luminescence Assay
Following incubation of cells in 96-well-plates, 70 µl of medium/well were replaced by DMEM
+ FCS but w/o phenol red and cells were cultured for another 24–48 h. Medium contained different
stimuli at different concentrations: 8-Br-cGMP: 0.5 mM, 1 mM, 2.5mM; 8-pCPT-cGMP: 100 µM, 200 µM,
500 µM; 8-Br-cAMP: 0.125 mM, 0.25 mM, 0.5 mM, 1.0 mM). Subsequently, 50 µL medium/well were
replaced with Bright-Glo™ Luciferase reagent. Plates were then measured in a luminescence capable
plate reader (GENios Pro, Tecan Trading AG, Maennedorf, Switzerland) after 2 min of shaking for a
1000 ms measurement time/well. The emitted photons per second were detected (stated as “Relative
Luminescence Unit RLU”) and normalized using the XFLuor4GeniosPro software, version 2 (Tecan
Trading AG, Maennedorf, Switzerland).
4.6. Statistical Analysis
Results are expressed as mean ± SEM, whereas n represents technical replicates. Calculation of
statistical differences was performed using GraphPad Prism 5. Unpaired Student’s t-test (two-tailed,
confidence interval 95%) was used for calculation of significant differences between two groups,
characterized in figures by *(with Welch’s correction if unequal variances were assumed, then
characterized in figures by +). p-values < 0.05 were considered significant (*, +), <0.01 and <0.001
highly significant (**, ++ and ***, +++, respectively), a non-significant difference was marked as n.s.
For calculation of significant differences between more than 2 groups, one-way analysis of variance
(ANOVA) followed by the Bonferroni post-test was performed with the same levels of significance as
above (characterized in figures by +, ++ and +++).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/4/
1180/s1.
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